CN115244079A - 结合人ngf的抗体、其制备方法和用途 - Google Patents

结合人ngf的抗体、其制备方法和用途 Download PDF

Info

Publication number
CN115244079A
CN115244079A CN202180015926.6A CN202180015926A CN115244079A CN 115244079 A CN115244079 A CN 115244079A CN 202180015926 A CN202180015926 A CN 202180015926A CN 115244079 A CN115244079 A CN 115244079A
Authority
CN
China
Prior art keywords
antibody
seq
antigen
human ngf
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180015926.6A
Other languages
English (en)
Inventor
朱祯平
黄浩旻
陈建鹤
郭伟
赵杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Original Assignee
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Guojian Pharmaceutical Shanghai Co Ltd filed Critical Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Publication of CN115244079A publication Critical patent/CN115244079A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

本发明提供了一种结合人NGF的抗体或其抗原结合片段，能够有效结合人NGF，阻断NGF‑TrKA的信号通路，应用于制备治疗NGF过表达的疾病(例如创伤、炎症、慢性疼痛)的药物，具有良好的临床应用前景。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN202180015926.6A 2020-04-26 2021-04-06 结合人ngf的抗体、其制备方法和用途 Pending CN115244079A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020103370557 2020-04-26
CN202010337055.7A CN113549150A (zh) 2020-04-26 2020-04-26 结合人ngf的抗体、其制备方法和用途
PCT/CN2021/085534 WO2021218574A1 (zh) 2020-04-26 2021-04-06 结合人ngf的抗体、其制备方法和用途

Publications (1)

Publication Number Publication Date
CN115244079A true CN115244079A (zh) 2022-10-25

Family

ID=78101480

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010337055.7A Pending CN113549150A (zh) 2020-04-26 2020-04-26 结合人ngf的抗体、其制备方法和用途
CN202180015926.6A Pending CN115244079A (zh) 2020-04-26 2021-04-06 结合人ngf的抗体、其制备方法和用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010337055.7A Pending CN113549150A (zh) 2020-04-26 2020-04-26 结合人ngf的抗体、其制备方法和用途

Country Status (3)

Country Link
CN (2) CN113549150A (zh)
TW (1) TWI773264B (zh)
WO (1) WO2021218574A1 (zh)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00226B (me) * 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
CN109929035B (zh) * 2017-12-15 2022-06-28 安源医药科技（上海）有限公司 抗人ngf抗体及其制备方法和用途

Also Published As

Publication number Publication date
CN113549150A (zh) 2021-10-26
TW202140548A (zh) 2021-11-01
TWI773264B (zh) 2022-08-01
WO2021218574A1 (zh) 2021-11-04

Similar Documents

Publication Publication Date Title
JP2023075294A (ja) 抗ｃｄ４７抗体及びその応用
WO2021155861A1 (zh) 人胸腺基质淋巴细胞生成素单克隆抗体及其应用
CN111615519B (zh) 结合人il-5的单克隆抗体、其制备方法和用途
US20200347130A1 (en) CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
CA3118775A1 (en) Anti-cd73 antibody, antigen-binding fragment thereof and application thereof
CN112041347B (zh) 结合人il-4r的抗体、其制备方法和用途
TWI797609B (zh) 抗pd-1和pd-l1的四價雙特異性抗體
US20230138315A1 (en) Anti-angptl3 antibody and use thereof
WO2021098822A1 (zh) 一种双特异性抗体
CN112513088B (zh) 抗ox40抗体、其抗原结合片段及其医药用途
CN112480254A (zh) 抗人白细胞介素-33受体的抗体及其制备方法和应用
CN112480250B (zh) 一种抗人骨桥蛋白的抗体及其应用
TW202334222A (zh) 結合gprc5d的抗體及其用途
CN115244079A (zh) 结合人ngf的抗体、其制备方法和用途
CN112480252B (zh) 抗白细胞介素-33抗体及其制备方法和应用
CN112279913B (zh) 一种抗人il-6单克隆抗体及应用
CN114395042B (zh) 抗il-33人源化抗体及其应用
CN114761434B (zh) Pd-1抗体及其制备方法与应用
WO2022257900A1 (zh) 抗masp-2抗体及其用途
EP4059963A1 (en) Molecule capable of binding to human 4-1bb, and application of molecule
JP2024509369A (ja) 抗ｐｄ－ｌ１抗体及びその使用
CN117924481A (zh) 抗犬il-31单克隆抗体及其应用
KR101042579B1 (ko) 아이소타입 이뮤노글로빈 에이인 신규한 ｒｂｐ４ 특이적인 항체 ａｇ１０２
CN116063480A (zh) 抗细胞角蛋白18抗体及其制备方法和应用
CN115975020A (zh) 靶向sars-cov-2s蛋白的抗原结合蛋白及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination